Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity.

Este estudio ha sido identificado como potencialmente de alto impacto. La métrica de alto impacto de OE, basada en la inteligencia artificial, estima la influencia que puede tener un artículo integrando señales procedentes tanto de la revista en la que se publica como del contenido científico del propio artículo. Desarrollado mediante el procesamiento del lenguaje natural más avanzado, el modelo de Alto Impacto de OE predice con mayor precisión el futuro rendimiento de las citas de un estudio que el factor de impacto de la revista por sí solo. Esto permite reconocer antes las investigaciones clínicamente significativas y ayuda a los lectores a centrarse en los artículos con más probabilidades de configurar la práctica futura.

Resumen del estudio

2339 adults with obesity without diabetes were randomized to receive once-weekly subcutaneous retatrutide (4 mg, 9 mg, or 12 mg) or placebo. The primary outcomes of interest were percentage change in body weight, change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain scores among patients with knee osteoarthritis, and change in the apnea–hypopnea index (AHI) among patients with obstructive sleep apnea. Secondary outcomes included weight reduction thresholds, waist circumference, cardiometabolic measures, physical functioning, quality of life, and adverse events. Outcomes were assessed at 80 weeks, with an extension phase evaluating weight loss at 104 weeks. Overall, the results revealed that retatrutide produced significantly greater weight loss than placebo, with reductions reaching 25.0% at the 12-mg dose compared with 3.9% with placebo. Retatrutide also significantly reduced knee osteoarthritis pain and obstructive sleep apnea severity. These findings suggested that retatrutide was effective for substantial weight reduction while improving important obesity-related complications.